Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that the China Food and Drug Administration (CFDA) has approved the Company's application to conduct a Phase 2 global clinical trial in ovarian clear cell carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.

30 Mar 2015

UCSF professor wins Vilcek Prize in Biomedical Science

Peter Walter was chosen as winner of the Vilcek Prize in Biomedical Science for his pioneering work on how proteins are transported between cellular compartments and for unraveling the components of a regulatory mechanism that cells use to handle stress tied to the aggregation of misshapen proteins.

29 Mar 2015

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, China.

25 Mar 2015

Researchers successfully generate cells of immune system to target, destroy cancer cells

Researchers at the Max Delbrück Center for Molecular Medicine Berlin-Buch and Charité - Universitätsmedizin Berlin, Campus Berlin-Buch, have succeeded in generating cells of the immune system to specifically target and destroy cancer cells.

20 Mar 2015

Janssen announces acquisition of XO1

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab.

19 Mar 2015

Vaxil Bio's ImMucin receives EMA orphan drug designation for treatment of Multiple Myeloma

Vaxil Bio, a leading developer of immunotherapeutic products to treat cancer and infectious diseases, reports today that its lead drug candidate, ImMucin has received orphan drug designation from the European Medicines Agency of the European Commission for the treatment of Multiple Myeloma (MM), a blood cancer.

16 Mar 2015

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).

12 Mar 2015

One World Cannabis, Sheba Academic Medical Center ink collaboration agreement

OWC Pharmaceutical Research Corp.'s wholly owned subsidiary One World Cannabis Ltd. signed a collaboration agreement with Sheba Academic Medical Center, the largest hospital in Israel and in the Middle East.

11 Mar 2015

Kyprolis demonstrates superiority over velcade in patients with relapsed multiple myeloma in head-to-head endeavor trial

Patients Receiving Kyprolis Lived Twice as Long without Disease Progression

2 Mar 2015

Findings reveal variations between countries and regions in use of HSCT procedure

Since the first experimental bone marrow transplant over 50 years ago, more than one million hematopoietic stem cell transplantations (HSCT) have been performed in 75 countries, according to new research charting the remarkable growth in the worldwide use of HSCT, published in The Lancet Haematology journal.

28 Feb 2015

New NCCN Guidelines for treating Acute Lymphoblastic Leukemia

According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Acute Lymphoblastic Leukemia (ALL), the treatment approach to ALL is one of the most complex and intensive programs in cancer therapy.

24 Feb 2015

President of MD Anderson selected as new fellow of AACR Academy

Ron DePinho, M.D., president of The University of Texas MD Anderson Cancer Center, will be inducted as a new fellow of the American Association for Cancer Research Academy. He joins 10 other cancer leaders in the prestigious academy that recognizes people who have made significant contributions to cancer research.

18 Feb 2015

Biotech investor invests in InterCure to increase stake in XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that Israeli biotech investor Alex Rabinovich, its largest shareholder, increased his stake in the Company through his investment in InterCure, an XTL subsidiary, and recent purchases of XTL stock in the market.

17 Feb 2015

Harmless plant extract can help treat Cushing Disease

Cushing Disease, not to be confused with Cushing's Syndrome, is caused by a tumour in the pituitary gland in the brain. The tumour secrets increased amounts of the stress hormone adrenocorticotropin (ACTH) followed by cortisol release from the adrenal glands leading to rapid weight gain, elevated blood pressure and muscular weakness.

16 Feb 2015

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals plc announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease (VOD), a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy.

13 Feb 2015

Damon Runyon Cancer Research Foundation names 15 new Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 15 new Damon Runyon Fellows at its fall Fellowship Award Committee review. The recipients of this prestigious, four-year award are outstanding postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators across the country.

31 Jan 2015

Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. Increased understanding of the microenvironmental interactions between malignant plasma cells and the bone marrow niche, and their role in disease progression and acquisition of therapy resistance, has helped the development of novel therapeutic drugs for use in combination with cytostatic therapy.

20 Jan 2015

New research helps explain why pancreatic cancer is so lethal

New research from the University of Michigan Comprehensive Cancer Center helps explain why pancreatic cancer is so lethal, with fewer than a third of patients surviving even early stage disease.

16 Jan 2015

$Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies$

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies.

13 Jan 2015

BioLight invests in newly-formed ophthalmic company

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its investment in a newly-formed ophthalmic company that has licensed-in a world-wide drug-delivery platform from the Hebrew University, Israel, that has the potential to enable more efficient and safer delivery of eye drops.

12 Jan 2015

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

UCSF professor wins Vilcek Prize in Biomedical Science

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

Researchers successfully generate cells of immune system to target, destroy cancer cells

Janssen announces acquisition of XO1

Vaxil Bio's ImMucin receives EMA orphan drug designation for treatment of Multiple Myeloma

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

One World Cannabis, Sheba Academic Medical Center ink collaboration agreement

Kyprolis demonstrates superiority over velcade in patients with relapsed multiple myeloma in head-to-head endeavor trial

Findings reveal variations between countries and regions in use of HSCT procedure

New NCCN Guidelines for treating Acute Lymphoblastic Leukemia

President of MD Anderson selected as new fellow of AACR Academy

Biotech investor invests in InterCure to increase stake in XTL Biopharmaceuticals

Harmless plant extract can help treat Cushing Disease

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Damon Runyon Cancer Research Foundation names 15 new Damon Runyon Fellows

Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

New research helps explain why pancreatic cancer is so lethal

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

BioLight invests in newly-formed ophthalmic company

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in